ABBOTINDIA · NSE
Abbott India Limited
₹26,525
+3.23% (+₹830)
Prev. close
₹25,695
Volume
11,142
Delivery %
52.3%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Abbott India Ltd., recommending a buy at the current price of ₹32,500 with a target price of ₹35,500 within t…” | Marketsmith India AnalysisMarketsmith India | Abbott India Ltd. | MISS | |
| “Bullish on Abbott India Ltd., recommending a buy at ₹32,500 with a target price of ₹35,500 in two to three months and a …” | Marketsmith India AnalysisMarketsmith India | Abbott India Ltd. | MISS | |
| “Bullish on Abbott India, which broke out from a rectangular pattern on weekly charts in May 2025, opening room for the s…” | ETMarkets AnalysisETMarkets.com | Abbott India Ltd | MISS | |
| “Recommends buying Abbott India at ₹30,395.65, setting a stop loss at ₹29,200 for a target price of ₹32,000. The stock is…” | Sumeet BagadiaChoice Equity Broking | Abbott India Ltd | MISS | |
| “Axis Securities recommends a 'BUY' on Abbott India Ltd. with a target price of Rs 31,420, implying a 10% upside from the…” | Axis Securities AnalysisAxis Securities | Abbott India Ltd. | PENDING |
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Abbott India Ltd, recommending a buy in the range of ₹29,000–30,000 with a profit goal of ₹34,000 and a stop …” | Marketsmith India AnalysisMarketsmith India | Abbott India Ltd | — | |
| “Recommends buying Abbott India Ltd. in the range of ₹29,000–30,000, targeting a profit goal of ₹34,000 within a 3–4 mont…” | Marketsmith India AnalysisMarketsmith India | Abbott India Ltd. | — |
Fundamentals
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Kartik Rajendran
Headquarters
Mumbai
Employees
3,679
Website
abbott.co.inExchange
View on NSE ↗Key stats
Market cap
₹57,628.11 Cr
P/E ratio (TTM)
35.7
Dividend yield
2.03%
EPS (TTM)
₹759.86
Beta (1Y · daily vs NIFTY 50)
0.25
Beta (5Y · monthly vs NIFTY 50)
0.07
Shares float
51.93 L
EPS · quarter ended Jun 2026
₹201.66
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹4,996.48 Cr | ₹5,502.88 Cr | ₹6,097.18 Cr | ₹6,684.73 Cr | ₹7,217.19 Cr | |
| ₹3,916.75 Cr | ₹4,229.06 Cr | ₹4,479.43 Cr | ₹4,797.78 Cr | ₹5,137.92 Cr | |
PROFIT BEFORE TAX | ₹1,079.73 Cr | ₹1,273.82 Cr | ₹1,617.75 Cr | ₹1,886.95 Cr | ₹2,079.27 Cr |
| ₹281.03 Cr | ₹324.41 Cr | ₹416.53 Cr | ₹472.51 Cr | ₹527.25 Cr | |
| ₹801.62 Cr | ₹953.03 Cr | ₹1,201.24 Cr | ₹1,409.02 Cr | ₹1,551.17 Cr | |
PROFIT FOR THE YEAR | ₹798.70 Cr | ₹949.41 Cr | ₹1,201.22 Cr | ₹1,414.44 Cr | ₹1,552.02 Cr |
| ₹2.92 Cr | ₹3.62 Cr | ₹2.00 L | ₹-5.42 Cr | ₹-85.00 L | |
Basic and Diluted - (Face value of " 10 each) | 375.86 | 446.78 | 565.28 | 665.62 | 730.36 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹3,840.45 Cr | ₹4,224.12 Cr | ₹4,555.51 Cr | ₹5,193.49 Cr | ₹5,917.31 Cr | ₹6,501.93 Cr | |
| ₹3,840.45 Cr | ₹4,224.12 Cr | ₹4,555.51 Cr | ₹5,193.49 Cr | ₹5,917.31 Cr | ₹6,501.93 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.
All years: standalone statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹-85.56 Cr | ₹106.96 Cr | ₹52.07 Cr | ₹268.85 Cr | ₹-118.26 Cr | |
| ₹947.66 Cr | ₹893.39 Cr | ₹1,212.81 Cr | ₹1,011.84 Cr | ₹1,319.24 Cr | |
| ₹-395.84 Cr | ₹-147.71 Cr | ₹-416.03 Cr | ₹182.18 Cr | ₹-371.38 Cr | |
| ₹-637.38 Cr | ₹-638.72 Cr | ₹-744.71 Cr | ₹-925.17 Cr | ₹-1,066.12 Cr | |
Cash and cash equivalents at the beginning of the year | ₹218.27 Cr | ₹132.71 Cr | ₹239.67 Cr | ₹291.74 Cr | ₹560.59 Cr |
Cash and cash equivalents at the end of the year (Refer Note 10) | ₹132.71 Cr | ₹239.67 Cr | ₹291.74 Cr | ₹560.59 Cr | ₹442.33 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Abbott India Limited | ₹54,823.20 Cr | ₹27,120 | 34.0 | 11.48 | 32.5% | 0.04 | +8.1% | -7.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Abbott India Q2 FY27 EBITDA Climbs to Rs. 568 Cr
Abbott India reported Q2 FY27 operating EBITDA of Rs 568 crore, up from Rs 502 crore a year earlier, and revenue from operations surpassed Rs 1,951 crore, an 11.03% YoY increase. Net profit rose 9.19% to Rs 453.45 crore, reflecting strong domestic demand and cost discipline, supporting its position in the Indian pharmaceutical market.